Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion.

 

Albert M. Baehny, Chairman, Lonza commented: “Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure and identity and refining our focus as a pure-play partner to the healthcare industry. As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth while delivering value for our customers, employees and shareholders.

 

“I wish to thank the leadership teams and all employees in the Specialty Ingredients business for their continuing dedication and professionalism during the transition period. We remain close neighbors with the Specialty Ingredients business at some of our sites, so we look forward to continuing to collaborate with the new company and wish it much success under its new ownership.”

 

The agreement between both parties was previously announced on 8 February 2021.